Zhang Na, Cao Caineng, Zhu Yuan, Liu Peng, Liu Luying, Lu Ke, Luo Jialin, Zhou Ning
Department of Radiation Oncology, Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
Oncol Lett. 2017 Feb;13(2):1014-1018. doi: 10.3892/ol.2016.5483. Epub 2016 Dec 12.
The aim of the present study was to summarize the clinical characteristics of primary breast lymphoma (PBL) and evaluate its management approaches. A total of 29 patients newly diagnosed with PBL, and treated between April 2006 and May 2013, were analyzed retrospectively. The median survival follow-up time for all patients was 66.8 (range, 25.4-110.0) months. The results of the follow-up revealed 22 living lymphoma-free patients and 7 patients who had succumbed to PBL. Of the 7 deceased patients, 6 had succumbed to lymphoma and 1 to chemotherapy-associated hepatic failure. In total, 1 patient who presented with bilateral breast lymphoma developed left breast relapse following lumpectomy and chemotherapy, 2 patients developed a bone marrow relapse, 1 patient developed lung and mediastinal lymph node relapses, and 1 patient developed a skin relapse. The Kaplan-Meier estimator predicted 5-year overall survival and progression-free survival rates for all patients of 74.4 and 74.6%, respectively. PBL appears to be a rare disease with a good overall prognosis and low incidence of local relapse, following chemotherapy alone or in combination with other treatments. Further studies investigating the development of effective agents for use in treatment-resistant patients are required.
本研究的目的是总结原发性乳腺淋巴瘤（PBL）的临床特征并评估其治疗方法。对2006年4月至2013年5月期间共29例新诊断为PBL并接受治疗的患者进行回顾性分析。所有患者的中位生存随访时间为66.8（范围25.4 - 110.0）个月。随访结果显示，22例患者无淋巴瘤存活，7例患者死于PBL。在7例死亡患者中，6例死于淋巴瘤，1例死于化疗相关的肝衰竭。共有1例双侧乳腺淋巴瘤患者在肿块切除和化疗后出现左乳复发，2例出现骨髓复发，1例出现肺和纵隔淋巴结复发，1例出现皮肤复发。Kaplan-Meier估计器预测所有患者的5年总生存率和无进展生存率分别为74.4%和74.6%。PBL似乎是一种罕见疾病，总体预后良好，单独化疗或与其他治疗联合使用后局部复发率较低。需要进一步研究开发用于治疗耐药患者的有效药物。
